ALKEM

Alkem Laboratories Ltd.

NSE: ALKEM

BSE: 539523

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

5,606.00-61.5 (-1.09%)

8 Jul, 12:00 AM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

93.9 / 100

Value Score

44.0 / 100

Price Momentum Score

81.9 / 100

QVM Score

92.1 / 100

Key Metrics

Market Cap

67028.10

P/E (TTM)

29.12

P/B

4.85

P/S (TTM)

4.56

EV/EBITDA

21.32

CAPE (5Y)

37.69

ROE (TTM)

17.84

ROCE (TTM)

17.37

ROA (TTM)

11.94

Avg 3Y ROE

18.61

Earnings 3Y CAGR

32.74

Sales 3Y CAGR

8.25

Sales 5Y CAGR

10.66

Debt/Equity

0.15

Consensus TP

6085.00

Strong Buy %

22.22

Promoter Holding

51.20

Pledged %

0.00

Stock Analysis

Fundamental analysis overview of Alkem Laboratories Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Strong price momentum

Price Momentum score of 81.9 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term

What is Price Momentum score?

81.9 / 100

Analysts have been raising forward EPS estimates

Analyst EPS estimate (consensus) for forward EPS has increased by 3.69% in the last 3 months, indicating earnings momentum

What is Earnings upgrade (3M)?

High and stable operating margin

The company reported strong operating margin of 17.83% for 12-month ended 31 Mar 2026 and operating margin improved marginally by 121 bps from 1 year ago

What is Operating profit margin?

Moderate revenue growth and above median growth of industry

The company delivered moderate revenue growth of 13.48% for 12-month ended 31 Mar 2026 and the growth was 2.24 percentage points higher than median growth of industry

What is Sales growth (1Y)?

Median: 11.24

Value 13.48

-82.35114662

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.15 as on 31 Mar 2026 and Debt to Equity increased marginally by 0.03 in the last 1 year

What is Debt to Equity?

Consistently pays dividend

The company has not missed dividend payments once in the last 10 financial years

What is Dividend streak?

Company is net cash

The company is net cash i.e., cash and cash equivalents exceed total debt indicating a healthy balance sheet

What is Net Debt ?

Negative

Expensive and at same valuation levels as industry median P/E

PE TTM of 29.12 indicates that the stock is expensive on a standalone basis. Discount to industry median P/E is modest at -4.12%

What is P/E Ratio?

Median: 30.37

Value 29.12

-215.443255.34

Low EPS growth and in line with median growth of industry

The company delivered low EPS growth of 6.29% for 12-month ended 31 Mar 2026 and the growth was 1.83 percentage points lower than median growth of industry

What is EPS growth (1Y)?

Low dividend yield

The company has a low dividend yield of 0.91%

What is Dividend yield?

Neutral

High ROE but declining trend

The company reported strong ROE of 17.84% for 12-month ended 31 Mar 2026 but ROE declined by -158 bps from 1 year ago

What is ROE (FY)?

Company's earnings are of moderate quality

Earnings quality score of 54.8 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

54.8 / 100

Financial Snapshot

See detailed analysis

Multi-year trends for Alkem Laboratories Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Alkem Laboratories Ltd. Shareholding Pattern

Quarterly breakdown of Alkem Laboratories Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Promoter	65.88	62.43	62.43	62.43	60.16	58.84	58.84	57.13	57.13	57.14	57.16	57.16	57.16	57.16	56.74	56.74	56.74	56.38	55.66	55.66	55.13	53.04	51.20	51.20	51.20
Indian Promoter	65.88	62.43	62.43	62.43	60.16	58.84	58.84	57.13	57.13	57.14	57.16	57.16	57.16	57.16	56.74	56.74	56.74	56.38	55.66	55.66	55.13	53.04	51.20	51.20	51.20
Foreign Promoter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Institutions	15.41	15.76	16.81	17.04	17.62	18.99	19.32	19.34	19.55	19.77	20.19	20.85	21.13	21.98	23.67	24.40	24.74	27.26	28.23	28.16	28.83	30.91	31.41	31.51	31.55
Mutual Funds / UTI	8.55	7.90	7.69	6.89	6.89	8.40	7.95	7.25	7.52	7.85	9.42	10.06	10.19	11.45	13.05	12.08	11.92	14.72	14.94	14.01	14.97	16.67	16.94	16.06	15.57
FI/Bank/Insurance	2.67	3.73	4.80	5.72	6.08	5.88	5.83	6.51	6.41	6.03	5.84	5.87	6.00	3.98	3.49	2.86	2.75	2.85	3.18	2.83	3.20	3.62	3.62	3.96	4.18
Govt	0.24	0.24	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FII	3.64	3.49	3.92	4.08	4.42	4.50	5.33	5.40	5.41	5.67	4.46	4.41	4.44	5.63	6.03	8.49	9.11	8.69	9.02	10.15	9.40	9.11	9.47	9.97	10.15
Other Institutions	0.32	0.40	0.40	0.35	0.23	0.21	0.21	0.18	0.21	0.22	0.47	0.51	0.50	0.91	1.09	0.97	0.96	0.99	1.09	1.17	1.25	1.51	1.37	1.52	1.64
Non-Institution	18.70	21.80	20.76	20.53	22.22	22.17	21.84	23.53	23.32	23.09	22.65	21.99	21.70	20.86	19.59	18.86	18.52	16.36	16.10	16.18	16.05	16.05	17.40	17.30	17.25
Bodies Corporate	0.78	0.25	0.22	0.20	0.14	0.15	0.13	0.14	0.12	0.16	0.13	0.09	0.11	0.12	0.11	0.10	0.10	0.11	0.12	0.11	0.11	0.18	0.08	0.09	0.08
Others (incl. Retail) No. of shareholders	17.92 73,496	21.55 88,422	20.54 96,745	20.33 97,557	22.08 94,394	22.02 92,688	21.71 86,526	23.39 86,039	23.20 81,046	22.93 83,286	22.52 78,978	21.90 75,812	21.59 72,726	20.74 66,233	19.48 68,867	18.76 64,391	18.42 64,965	16.25 68,736	15.98 73,636	16.07 82,760	15.94 83,082	15.87 78,483	17.32 66,049	17.21 63,388	17.17 61,686

Holdings and Presence

Indices and prominent investors with a stake in this stock.

Index Presence

#	Index	Weight	Rank
1	Nifty Pharma	3.62%	10 / 20
2	Nifty Healthcare	3.1%	13 / 20
3	Nifty Midcap 50	1.44%	37 / 50
4	Nifty Midcap 100	0.97%	43 / 100
5	Nifty Midcap 150	0.8%	43 / 149
6	NIFTY Large Midcap 250	0.42%	72 / 250
7	Nifty 500	0.17%	128 / 499
8	Nifty Total Market	0.16%	134 / 749

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Alkem Laboratories Ltd. shares as reported to NSE and BSE.

Name	Month	Transaction	Holding % pre transaction	Average price	Qty.	Transaction value
Mr. Deepak Kumar Singh Designated Person	March-2022	Market Sale (Disposal) 29th Mar 2022	2.43 %	₹ 3,609.42	25.00 k	₹ 9.02 cr
Mritunjay Kumar Singh Promoter & Director	March-2022	Market Purchase (Acquisition) 8th Mar 2022	6.38 %	₹ 3,158.04	1.64 k	₹ 51.89 lac
Mritunjay Kumar Singh Promoter & Director	March-2022	Market Purchase (Acquisition) 8th Mar 2022	6.38 %	₹ 3,184.96	3.36 k	₹ 1.07 cr
Dhananjay and Madhurima Singh Trust Promoter	February-2022	Market Purchase (Acquisition) 25th Feb 2022	0.00 %	₹ 3,275.00	1.05 k	₹ 34.39 lac
Dhananjay and Madhurima Singh Trust Promoter	February-2022	Market Purchase (Acquisition) 23rd Feb 2022	0.00 %	₹ 3,295.87	2.00 k	₹ 65.92 lac
Mr. Deepak Kumar Singh Designated Person	December-2021	Market Sale (Disposal) 30th Dec 2021	2.43 %	₹ 3,491.17	2.00 k	₹ 69.82 lac
Mr. Deepak Kumar Singh Designated Person	December-2021	Market Sale (Disposal) 27th Dec 2021	2.44 %	₹ 3,437.32	2.00 k	₹ 68.75 lac
Mr. Deepak Kumar Singh Designated Person	December-2021	Market Sale (Disposal) 23rd Dec 2021	2.44 %	₹ 3,435.82	5.00 k	₹ 1.72 cr
Deepak Kumar Singh Designated Person	November-2021	Market Sale (Disposal) 18th Nov 2021	2.44 %	₹ 3,572.56	5.00 k	₹ 1.79 cr
Mr. Balmiki Prasad Singh Promoter & Director	October-2021	Off Market (Acquisition) 5th Oct 2021	0.06 %	₹ 0.00	50.27 k	₹ 0.00

Corporate Actions

History of Alkem Laboratories Ltd. dividends, bonus issues, stock splits, rights issues, and other corporate events.

Dividend₹ 10/share
Record date: 7th Aug 2026Ex-date: 7th Aug 2026
Announced on: 28th May 2026
Dividend₹ 43/share
Record date: 20th Feb 2026Ex-date: 20th Feb 2026
Announced on: 23rd Jan 2026
Dividend₹ 8/share
Record date: 8th Aug 2025Ex-date: 8th Aug 2025
Announced on: 29th May 2025
Dividend₹ 37/share
Record date: 14th Feb 2025Ex-date: 14th Feb 2025
Announced on: 28th Jan 2025
Dividend₹ 5/share
Record date: 10th Aug 2024Ex-date: 9th Aug 2024
Announced on: 29th May 2024

Company Profile

Overview of Alkem Laboratories Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Alkem Laboratories Ltd. is an India-based pharmaceutical company engaged in the development, manufacturing, and sale of pharmaceutical products. The Company operates in a single business segment-Pharmaceuticals. It produces branded generics, generic drugs, active pharmaceutical ingredients (APIs), a...

Key personnel

Mr. Nitin Agrawal

President - Finance, Chief Financial Officer

Mr. Manish Narang

President - Legal, Compliance Officer, Company Secretary

Ms. Purvi Shah

Investor Relations

Ms. Purvi Shah

Investor Relations

Ms. Purvi Shah

Investor Relations

Mr. Basudeo Narain SinghD

Executive Chairman of the Board

Mr. Sandeep SinghD

Managing Director, Executive Director

Mrs. Madhurima SinghD

Executive Director

View all

Incorporated on

08 Aug 1973

Last Annual

31 Mar 2026

Last Interim

31 Mar 2026

No. of Employees

IPO date

23 Dec 2015

Free Float

4,43,49,446

Website

https://www.alkemlabs.com/

Phone no.

+912239829999

Address

ALKEM HOUSE SENAPATI BAPAT MARG, LOWER PAREL, , 400013, India

Frequently Asked Questions

What is the current share price of Alkem Laboratories Ltd.?

The current share price of Alkem Laboratories Ltd. is ₹ 5,606.00 as of 8 Jul 2026.

What is the market capitalisation of Alkem Laboratories Ltd.?

The market capitalisation of Alkem Laboratories Ltd. stands at ₹ 67,028.10 Cr.

What is the PE ratio of Alkem Laboratories Ltd.?

The Price-to-Earnings (PE) ratio of Alkem Laboratories Ltd. is 29.12 as of the latest trailing twelve months data.

What is the ROE and ROCE of Alkem Laboratories Ltd.?

Alkem Laboratories Ltd. has a Return on Equity (ROE) of 17.84% and a Return on Capital Employed (ROCE) of 17.37% as per the latest financial reports.

What is the 52-week high and low of Alkem Laboratories Ltd.?

The 52-week high of Alkem Laboratories Ltd. is - and the 52-week low is -.

What is the dividend yield of Alkem Laboratories Ltd.?

The dividend yield of Alkem Laboratories Ltd. is 0.91% based on the current market price.

What is the FII and DII holding in Alkem Laboratories Ltd.?

Foreign Institutional Investors (FII) hold 10.15%, Domestic Institutional Investors (DII) hold 19.75% and retail/public investors hold 17.17% of Alkem Laboratories Ltd. shares.

What sector does Alkem Laboratories Ltd. belong to?

Alkem Laboratories Ltd. operates in the Healthcare sector. 50% of analysts have a Buy or Strong Buy rating on Alkem Laboratories Ltd. with a consensus target price of ₹ 6,085.00, implying 8.54% upside from current levels.

What is the beta of Alkem Laboratories Ltd.?

The beta of Alkem Laboratories Ltd. is 0.67, indicating its price volatility relative to the broader market. Over the past 1 year, Alkem Laboratories Ltd. has delivered an absolute return of 13.50%.

What is the RSI of Alkem Laboratories Ltd.?

The 14-day Relative Strength Index (RSI) of Alkem Laboratories Ltd. is 61.49, placing it approaching overbought territory. An RSI above 70 is considered overbought and below 30 is considered oversold.

Alkem Laboratories Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Alkem Laboratories Ltd. Shareholding Pattern

Holdings and Presence

Bulk, Block and Insider Trades

Corporate Actions

Company Profile

Frequently Asked Questions

Stock Analysis

Holdings and Presence

Corporate Actions

Company Profile